Last €13.03 EUR
Change Today +0.39 / 3.09%
Volume 839.3K
REC On Other Exchanges
Symbol
Exchange
REC is not on other exchanges.
As of 11:30 AM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

recordati spa (REC) Snapshot

Open
€12.63
Previous Close
€12.64
Day High
€13.11
Day Low
€12.63
52 Week High
02/28/14 - €13.35
52 Week Low
09/30/13 - €8.43
Market Cap
2.7B
Average Volume 10 Days
271.0K
EPS TTM
€0.72
Shares Outstanding
209.1M
EX-Date
04/28/14
P/E TM
18.2x
Dividend
€0.33
Dividend Yield
2.53%
Current Stock Chart for RECORDATI SPA (REC)

Related News

No related news articles were found.

recordati spa (REC) Related Businessweek News

No Related Businessweek News Found

recordati spa (REC) Details

Recordati S.p.A. is engaged in the research, development, manufacture, marketing, and sale of pharmaceuticals. It offers pharmaceuticals in various therapeutic areas, including cardiovascular, cosmetics, dermatology, dietary supplements, musculo-skeletal disorders and analgesia, pregnancy test, urology, OTC/non-prescription pharmaceuticals, allergy, antiinfectives, central nervous system, endocrinology, gastrointestinal, gynecology, obstetrics, nutrition and related areas, immunosuppressants, pediatrics, pneumology, hematology, oncology, respiratory, analgesia, antipyretics, cold preparations, radio contrast agent, and generics. The company’s flagship product is ZANIDIP (lercanidipine), a calcium-channel blocker for the treatment of hypertension. It also develops Zanipress for the treatment of hypertension; Carbaglu, which is approved in the European Union and is under Phase III clinical trials in the United States for the treatment of organic acidemias; REC 0482 for the treatment of benign prostatic hyperplasia, which is under Phase III clinical trials; and Cystadrops that is under Pre-registration in the European Union for the treatment of ocular cystinosis. In addition, the company develops REC 0438 for the treating overactive bladder in patients with spinal lesions and is under Phase I clinical trials; methadone for treating Cancer related pain and is under Phase IIIb clinical trials; Citrafleet for colonoscopy and is under Phase III clinical trials; and GRASPA for Acute lymphoblastic leukemia and is under Phase II/III clinical trials, as well as for Acute myeloid leukemia and is under Phase II b clinical trials. Further, the company produces pharmaceutical chemicals, such as active ingredients and intermediates for the generic drugs market. Recordati S.p.A has operations in Europe, Australasia, Africa, and the United States. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati S.p.A. is a subsidiary of Fimei S.p.A.

3,961 Employees
Last Reported Date: 03/7/14
Founded in 1926

recordati spa (REC) Top Compensated Officers

Chairman, Chief Executive Officer and General...
Total Annual Compensation: €1.4M
Compensation as of Fiscal Year 2013.

recordati spa (REC) Key Developments

Recordati SpA Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014

Recordati SpA Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 . Venue: The Grand Hyatt Hotel, New York, New York, United States.

Recordati SpA Announces Consolidated Earnings Results for the Second Quarter and First Half Year Ended June 30, 2014

Recordati SpA announced consolidated earnings results for the second quarter and first half year ended June 30, 2014. For the quarter, the company has reported that net income attributable to the equity holders of the parent was EUR 40.28 million, compared to EUR 32.52 million for the same quarter ended June 30, 2013. Revenue was EUR 247.26 million, compared to EUR 233.16 million for the same quarter ended June 30, 2013. For the six months, the company's EBITDA at 27.9% of sales, is EUR 141.9 million, an increase of 18.2% over the same period of the preceding year. Operating income, at 24.0% of sales, is EUR 121.8 million, an increase of 18.8%. Net income attributable to the equity holders of the parent was EUR 83.04 million, or EUR 0.393 per diluted share, compared to EUR 70.29 million, or EUR 0.331 per diluted share, for the same period ended June 30, 2013. Revenue was EUR 507.62 million, compared to EUR 477.73 million for the same period ended June 30, 2013.

Recordati SpA, H1 2014 Earnings Call, Jul 29, 2014

Recordati SpA, H1 2014 Earnings Call, Jul 29, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
REC:IM €13.03 EUR +0.39

REC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €11.52 EUR -0.19
Faes Farma SA €2.10 EUR -0.01
Ipsen SA €38.62 EUR -0.49
Meda AB kr99.10 SEK +0.55
Orion OYJ €29.16 EUR -0.52
View Industry Companies
 

Industry Analysis

REC

Industry Average

Valuation REC Industry Range
Price/Earnings 17.1x
Price/Sales 2.5x
Price/Book 3.1x
Price/Cash Flow 17.0x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RECORDATI SPA, please visit www.recordati.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.